Massive gene hunt launched to unlock Alzheimer's secrets
NCT ID NCT05010603
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study aims to find genes that increase the risk of developing Alzheimer's disease. Researchers are recruiting 10,000 people, including those with Alzheimer's and their family members, from all ethnic backgrounds. By analyzing DNA, they hope to discover new genetic clues that could lead to better understanding and future treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 10,000 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Nov 2016
- Expected to finish
-
Apr 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
The investigators intend to recruit individuals from: 1) community-based studies; 2) the Alzheimer's Disease Research Center Memory Disorders Center; 3) the private offices of the study neurologists; 4) public recruitment; 5) referrals from the Alzheimer's Association; 6) referrals from the NCRAD; 7)previously unidentified members of existing families not previously recruited. The investigators will also use advertisements such as radio, television and newspapers.
- Ages
-
55 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Established diagnosis of definite or probable AD or have a diagnosis of a related neurodegenerative disorder such as Frontotemporal Dementia (FTD) or Lewy Body Dementia (LBD) (will also recruit sporadic FTD and LBD) cases. * a living sibling with probable or possible AD; * a third living relative affected with AD (onset age 50 or older) or unaffected (60 or older); * participants in the proband's generation with an identified companion serving as an informant; * participants who have capacity to consent or participants lacking capacity to consent with a surrogate/proxy in place to provide consent. Exclusion Criteria: * failure to identify an appropriate informant; * uncertainty of the clinical diagnosis of Alzheimer's disease or other related disorder; * discovery of additional diagnosis that could account for the clinical manifestations; * unwillingness to participate; * failure to identify a living sibling with AD or other related disorder (except in the cases of sporadic FTD and sporadic LBD); * participants lacking the capacity to consent who do not have a surrogate or proxy or next of kin to provide consent.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Alzheimer disease are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
12 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Columbia University Irving Medical Center
RECRUITINGNew York, New York, 10032, United States
-
Indiana University
RECRUITINGBloomington, Indiana, 47405, United States
-
Joanne Norton
RECRUITINGSt Louis, Missouri, 63130, United States
-
Mayo Clinic
RECRUITINGRochester, Minnesota, 55901, United States
-
NCRAD at Indiana University
RECRUITINGIndianapolis, Indiana, 46202, United States
-
North Carolina State University
RECRUITINGRaleigh, North Carolina, 27695, United States
-
Rush University
RECRUITINGAurora, Illinois, 60612, United States
-
University of Miami
RECRUITINGMiami, Florida, 33124, United States
-
University of Pittsburgh
RECRUITINGPittsburgh, Pennsylvania, 15213, United States
-
University of Texas Southwestern
RECRUITINGDallas, Texas, 75390, United States
-
University of Washington
RECRUITINGWashington D.C., District of Columbia, 98105, United States
-
University of Washington
RECRUITINGSeattle, Washington, 98195, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Glutathione, brain metabolism and inflammation in Alzheimer's disease
- A multicenter, open-label extension (OLE) study to evaluate the safety, pharmacodynamics, and clinical effects of WVE-004 in patients with C9orf72-associated amyotrophic lateral sclerosis (ALS) and/or frontotemporal dementia (FTD)
- Can an experimental infusion reach the brain to fight Alzheimer's?
- A new roadmap to predict Alzheimer's before memory fails
- Can a 500-Person study unlock Alzheimer's early signs?
- AI hunts for early clues to Parkinson's and Alzheimer's progression